Instil Bio, Inc. Form 8-K Summary
Business context and reporting period
Instil Bio, Inc. filed this Current Report on January 24, 2023, with the report signed on January 27, 2023. The filing concerns the company’s compliance with Nasdaq continued-listing requirements and does not report operating or financial results.
Financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material change versus the prior comparable period
On January 24, 2023, Nasdaq notified the company that its common stock had traded below the minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
- The notice had no immediate effect on the listing or trading of the common stock on The Nasdaq Global Select Market.
- The company has until July 24, 2023, to regain compliance by maintaining a bid price of at least $1.00 for at least 10 consecutive business days.
Outlook, risks, contingencies, and unusual items
If the company does not regain compliance by July 24, 2023, it may be eligible for an additional 180-day compliance period by transferring to The Nasdaq Capital Market, subject to meeting that market’s applicable requirements and providing timely written notice.
If the company neither regains compliance nor completes an eligible transfer before the applicable deadline, Nasdaq may issue a delisting determination. The company could appeal such a determination, but the filing states that there can be no assurance the appeal would succeed. The company intends to monitor its stock price and consider available actions, but provides no assurance that it will regain compliance or satisfy other Nasdaq listing criteria.
Important facts for investors to verify
- Whether the common stock regained a bid price of at least $1.00 for the required consecutive trading days by July 24, 2023.
- Whether the company sought or completed a transfer to The Nasdaq Capital Market.
- Any subsequent Nasdaq delisting notice, appeal, hearing, or continued-listing determination.
- Whether the company remained compliant with Nasdaq’s other listing requirements.